Minimally Invasive Brain Science (02172): NuWisMen® Self™ Liquid Embolizer Enters NMPA's Green Channel for Innovation

^{Zhitong Finance App News, Minimally Invasive Brain Science (02172) issued an announcement. The NuWisMen® self™ liquid embolizer developed by the Group passed the China Drug Administration (NMPA) special review application for innovative medical devices and entered the special review process (green channel).} This selection is the Group's 8th product to be included in the NMPA's special review of innovative medical devices. It completes the product puzzle in the cerebrovascular malformation treatment section and further enhances the coverage of interventional solutions for all scenarios of cerebrovascular diseases.

Cerebrovascular malformations include common lesions such as cerebral arteriovenous malformation (BaVM) and dural arteriovenous fistula (DaVF). Interventional embolization is the first clinical choice for complex lesions with deep locations, involving functional areas, aneurysms, or high-flow fistulas, and is also an important combination treatment.

The Group is committed to the development and promotion of innovative medical solutions. Currently, there are 29 neurological interventional products covering major diseases such as aneurysms, stenosis, and embolization. ^{The Group's 8 products are included in the NMPA Green Channel for Innovative Medical Devices. The remaining 7 are Tubridge ® Midbridge™ blood-flow guided dense mesh stents, Bridge® Zhiqiao™ vertebral artery rapamycin targeted elution stents, Tigertriever® intracranial embolization stents, Rebridge® Ruiqiao® intracranial artery stents, The StraitPass ® Inquisitor™ disposable hematoma suction device, the NuFairy® Goddess™ absorbable spring ring, and the Artemis Dream ® Chanjuan™ self-inflating intracranial rapamycin-eluting stent system, 3 of which have already been marketed.}